StreetAlpha.app
Home › Stocks › NKTR

Nektar Therapeutics (NKTR)

Healthcare
$30.20
▼ −7.19%
LAST CLOSE · NOV 20

Nektar Therapeutics is a San Francisco biopharmaceutical company developing immunotherapy drugs for autoimmune diseases and cancer. It last closed at $30.20 on Nov 20, down 7.19% on the day. The next earnings report for NKTR is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, NKTR reported EPS of -$1.63 on revenue of $9.4M, with revenue down 20.4% from a year ago. Over its last 8 reports the stock moved an average of 2.8% the session after earnings. Over the last 12 months NKTR insiders bought $0 of stock on the open market and sold $2.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is NKTR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NKTR.

Key Stats

Last 12 months
Results
Revenue
$52.2M
−16.6% vs a year ago
Net income
−$177.3M
−339.7% margin
EPS (diluted)
−$6.19
Free cash flow
−$257.5M
−493.4% margin
Valuation
Market cap
$1.0B
34.2M shares
P/E
–
No P/E while losing money
Price to sales
19.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$34.7M
At Sep 30
Shareholder equity
$849.7M
Shares outstanding
34.2M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $101.9M$101.9MFY2021FY2022: $92.1M$92.1MFY2022FY2023: $90.1M$90.1MFY2023FY2024: $98.4M$98.4MFY2024FY2025: $55.2M$55.2MFY2025

From NKTR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 11
Estimated date · After the close
Reported EPS
-$1.63
Quarter ended Sep 2026
Year ago EPS
-$1.87
Same quarter last year
Revenue
$9.4M
−20.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.59Dec '24Mar 2025: -$3.62Mar '25Jun 2025: -$2.95Jun '25Sep 2025: -$1.87Sep '25Dec 2025: -$1.59Dec '25Mar 2026: -$1.82Mar '26Jun 2026: -$1.23Jun '26Sep 2026: -$1.63Sep '26Latest -$1.63
Revenue by quarter
Dec 2024: $29.2MDec '24Mar 2025: $10.5MMar '25Jun 2025: $11.2MJun '25Sep 2025: $11.8MSep '25Dec 2025: $21.8MDec '25Mar 2026: $10.9MMar '26Jun 2026: $10.1MJun '26Sep 2026: $9.4MSep '26Latest $9.4M
How NKTR moved after its last 8 reports
Average move the session after a report ±2.8%
Nov 12, 2026After the close+0.1%
Aug 13, 2026After the close−3.8%
May 7, 2026After the close−1.8%
Mar 12, 2026After the close+4.1%
Nov 6, 2025After the close+1.5%
Aug 7, 2025After the close+6.0%
May 8, 2025After the close−4.9%
Mar 12, 2025After the close−0.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NKTRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NKTR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NKTR

Technical Analysis

NKTR · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 22% below its 20 day and 48% below its 50 day average. It is 115% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $30.13, and the nearest resistance the Pivot at $30.89.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 6.8%/day
Key levels
$109.0052 week high+260.9%
$64.96200 day average+115.1%
$58.39100 day average+93.3%
$44.6050 day average+47.7%
$39.10Swing high (Nov 11)+29.5%
$36.8320 day average+22.0%
$31.66Pivot R1+4.8%
$30.89Pivot+2.3%
$30.20Last close
$30.1352 week low−0.2%
$29.44Pivot S1−2.5%
Indicators
RSI (14)23.44Oversold below 30Oversold
MACD-2.95Below its signal lineBearish
Stochastic0.5Near the bottom of its rangeOversold
ADX (14)35.4Trending down
Williams %R-99.2Oversold below −80, overbought above −20Oversold
CCI (20)-306.9Oversold below −100, overbought above 100Oversold
Rate of change−18.9%Change over 10 sessionsBearish
ATR (14)$2.05Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NKTR

What happened before

See how NKTR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NKTR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NKTR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NKTRHow many large options trades hit NKTR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NKTR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲127 buying vs 110 selling
  • ●Held by funds -0.1 pts
  • ●Funds holding -1
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding244245−0.4%
In funds' top 1010100.0%
Held by funds105.0%105.1%−0.1 pts
New / increased38 / 8973 / 100−26.6%
Reduced / sold out69 / 4142 / 48+22.2%
Put/call ratio0.840.38+119.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NKTR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NKTR Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.5M15 sales · 3 insiders
85% of the selling was under pre-arranged trading plans.
2026-01 sold $138K2026-02 sold $44K2026-05 sold $42K2026-06 sold $1.9M2026-08 sold $43K2026-11 sold $22KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Jonathan ZalevskyChief R&D OfficerSale192$35.85$7K
Nov 17Howard W RobinPresident & CEOSale429$35.85$15K
Aug 18Howard W RobinPresident & CEOSale418$71.98$30K
Aug 18Jonathan ZalevskyChief R&D OfficerSale186$71.98$13K
Jun 30Jonathan ZalevskyChief R&D OfficerSale plan5,681$70.00$398K
Jun 17Howard W RobinPresident & CEOSale plan20,000$60.75$1.2M
Every insider buy and sale for NKTR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NKTR insider trades →

From SEC Form 4 filings by NKTR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTR is in one of them and how their past NKTR trades turned out.

NKTR in the AI portfolios
Loading…

NKTR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NKTR in an article yet. Here's the latest on the wider market.

NKTR in the news

NKTR Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Oct 2
Who traded NKTR · since 2018
Latest 2 filings
$1K – $15KTraded Jun 21, 2018Filed Oct 2, 2018
$1K – $15KTraded Jun 6, 2018Filed Oct 2, 2018
PersonTypeAmountTradedFiledDelay
Josh GottheimerD · NJSell$1K – $15KJun 21, 2018Oct 2, 2018103 d
Josh GottheimerD · NJBuy$1K – $15KJun 6, 2018Oct 2, 2018118 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California. It researches and develops drugs that act on the immune system, with programs aimed at autoimmune diseases such as atopic dermatitis and at cancer. Its main drug candidate, rezpegaldesleukin, is designed to increase the activity of regulatory T cells to help restore immune balance. The company's drugs are still in development, and they are intended for people living with autoimmune and inflammatory conditions.

Headquarters
San Francisco, CA
Founded
1990